VeonGen novel non-VEGF gene therapy

VeonGen's novel non-VEGF gene therapy is an experimental therapeutic candidate currently in preclinical development for the treatment of age-related macular degeneration (AMD). Developed by VeonGen (formerly ViGeneron), this program distinguishes itself from current standard-of-care treatments by targeting a novel, undisclosed biological pathway independent of vascular endothelial growth factor (VEGF). The therapy leverages VeonGen's proprietary viral vector technology, specifically designed for efficient retinal transduction following intravitreal administration. By addressing non-VEGF mechanisms, the therapy aims to provide a new treatment option for patients who do not respond adequately to existing anti-VEGF therapies, potentially offering improved visual outcomes and a reduced treatment burden through long-term transgene expression.

Other names

ViGeneron novel non-VEGF gene therapyVeonGen novel non-VEGF AMD gene therapyViGeneron novel non-VEGF AMD gene therapy